Notably, C151 in Keap1 is the target of the two Nrf2 activators that are in clinical use: dimethyl fumarate, for relapsing remitting multiple sclerosis, and omaveloxolone, for Friedreich's ataxia, as well as the isothiocyanate sulforaphane, a classical Nrf2 activator that has been employed in ∼90 clinical trials [[11], [12], [13]]. Here, NFE2L2 is linked to Friedreich ataxia.